Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit†

Saccà, F., Piro, R., De Michele, G., Acquaviva, F., Antenora, A., Carlomagno, G., Cocozza, S., Denaro, A., Guacci, A., Marsili, A., Perrotta, G., Puorro, G., Cittadini, A. and Filla, A. , Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit. Movement Disorders, n/a. doi: 10.1002/mds.23435

Tags: efficacy, safety, and tolerability, two single doses of Epoetin alfa, Friedreich's ataxia, subcutaneously, frataxin, did not affect hematocrit, cardiac function, and neurological scale, phlebotomy, lack of erythropoietic effect.

The benefits and limitations of animal models for translational research in neurodegenerative diseases

Nature Medicine 16, 1210 - 1214 (2010), doi:10.1038/nm.2224

Mathias Jucker is at the Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, and the DZNE-German Center for Neurodegenerative Diseases, Tübingen, Germany.